tCGM

AcronymDefinition
tCGMTransdermal Continuous Glucose Monitoring (Echo Therapeutics)
References in periodicals archive ?
14 October 2011 - US Echo Therapeutics Inc (NASDAQ:ECTE) said today it is commencing a study of its non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system, Symphony, in patients with Type 1 and Type 2 diabetes.
Echo intends to enroll up to 25 patients with either Type 1 or Type 2 diabetes and to compare data obtained from its Symphony tCGM System with both the YSI 2300 STAT Plus Glucose Analyzer and a commercially available professional-use glucometer.
"Scientific American is one of the best known scientific trade journals and this article significantly raises the visibility of our Symphony tCGM System and the Prelude SkinPrep System for transdermal drug delivery within the scientific community and with the general public, including potential investors," commented Patrick T.
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.
Symphony tCGM System supplier Echo Therapeutics Inc (NasdaqCM:ECTE) said on Thursday that it will receive a credit facility of up to USD20m from Platinum-Montaur Life Sciences LLC (Montaur).
The company is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.
Drug delivery company Echo Therapeutics Inc (Nasdaq:ECTE) reported on Thursday the receipt of patents covering its Prelude SkinPrep System as well as a notice of allowance for a US patent covering its Symphony tCGM System.
11/223,971, entitled "System and Method for Analyte Sampling and Analysis with Hydrogel", covering certain aspects of the biosensor in the Symphony tCGM System.
Echo Therapeutics Inc (Nasdaq: ECTE) a developer of transdermal medical products, announced on Tuesday that it is initiating clinical studies of its Symphony tCGM System in critical care patients.
Echo Therapeutics Inc (Nasdaq: ECTE), a developer of a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude SkinPrep System for transdermal drug delivery, announced on Tuesday a registered direct equity financing of approximately USD5.4m by issuing units.